Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-PRCRP-ACCCT: DoD Peer Reviewed Cancer, Advancing Cancer Care through Clinical Trials Award

Closed Closed September 27, 2023 Opportunity HT9425-23-PRCRP-ACCCT ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$28.8 million
• Expected awards6
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The PRCRP ACCCT Award supports clinical trials that will progress to the next stage of study or improve the standard of care for individuals living with cancer within at least one of the FY23 PRCRP Topic Areas. The ACCCT Award mechanism requires a clinical trial for transition of and the advancement of previously completed pre-clinical research to the clinic. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/ Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY23 PRCRP program announcements being offered. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, “regulatory agency” refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted. Key aspects of the PRCRP Award Mechanism: · Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 12 months after the award date and have recruited at least two study participants. · Impact: The proposed intervention(s) to be tested should offer significant potential for advancing to the next stage of clinical study, transition of results to fielded science, or improve the standard of care for at least one of the FY23 PRCRP Topic Areas and address one of the FY23 PRCRP Military Health Focus Areas and one of the FY23 PRCRP Overarching Challenges.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.